tipas : |
Laboratorija |
|
Mokslinių tyrimų Komandos : |
|
Autoriai : |
|
Pavadinimas : |
Nivolumab (Opdivo®) - Summary of Product Characteristics |
Numeris : |
Bristol Myers Squibb Pharmaceuticals 2022 |
|
Įrodymų lygis : |
|
fizinis stabilumas : |
|
Cheminis stabilumas : |
|
Kiti metodai : |
|
Komentarai : |
|
Junginių sąrašas
Nivolumab
|
 |
 |
 |
 |
1 >> 10 mg/ml |
2-8°C |
 |
30 |
 |
|
|
 |
 |
 |
1 >> 10 mg/ml |
25°C |
 |
24 |
 |
|
|
 |
 |
 |
1 >> 10 mg/ml |
2-8°C |
 |
7 |
 |
|
|
 |
 |
 |
1 >> 10 mg/ml |
25°C |
 |
8 |
 |
|
|
 |
 |
 |
10 mg/ml |
25°C |
 |
48 |
 |
|
|
 |
 |
 |
1 >> 10 mg/ml |
2-8°C |
 |
30 |
 |
|
|
 |
 |
 |
1 >> 10 mg/ml |
25°C |
 |
24 |
 |
|
|
 |
 |
 |
1 >> 10 mg/ml |
2-8°C |
 |
7 |
 |
|
|
 |
 |
 |
1 >> 10 mg/ml |
25°C |
 |
8 |
 |
|
|
 |
 |
 |
1 >> 10 mg/ml |
2-8°C |
 |
30 |
 |
|
|
 |
 |
 |
1 >> 10 mg/ml |
25°C |
 |
24 |
 |
|
|
 |
 |
 |
1 >> 10 mg/ml |
2-8°C |
 |
7 |
 |
|
|
 |
 |
 |
1 >> 10 mg/ml |
25°C |
 |
8 |
 |
|
|
|
|